Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*) (Incorporated in Bermuda with limited liability) (Stock Code: 897)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Reference is made to the joint announcement of Caister Limited ("**Caister**"), Wai Yuen Tong Medicine Holdings Limited (the "**Company**"), Wang On Group Limited ("**WOG**") and Easy One Financial Group Limited ("**EOG**") dated 4 May 2020 (the "**Joint Announcement**") in relation to, among other things, the proposed privatisation of EOG by Caister by way of a scheme of arrangement (under section 99 of the Companies Act 1981 of Bermuda) (the "**Scheme**"), the proposed withdrawal of listing of EOG and the possible major and connected transaction for the Company in relation to the effective disposal of the Company's shareholding in EOG (and the resultant acquisition of shares in WOG pursuant to the Scheme). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Joint Announcement.

The board of directors of the Company (the "**Board**" or the "**Directors**") is pleased to announce that Alliance Capital Partners Limited, a corporation licensed by the Securities and Futures Commission to carry out Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), has been appointed as the WYT IFA to provide recommendations to the WYT IBC and the Independent WYT Shareholders in relation to the terms of the WYT Disposal (and the resultant acquisition by the Company of the Consideration Shares). The letter of advice from the WYT IFA to the WYT IBC and the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the Company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the resultant acquisition by the Company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the Company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the Company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the Company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisition by the company of the Independent WYT Shareholders in respect of the WYT Disposal (and the resultant acquisi

^{*} For identification purpose only

by the Company of the Consideration Shares) will be included in the WYT Circular to be despatched by the Company to the WYT Shareholders.

By Order of the Board WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司*) Chan Chun Hong, Thomas Director

Hong Kong, 4 June 2020

As at the date of this announcement, the executive Directors are Mr. Tang Ching Ho, Mr. Chan Chun Hong, Thomas, Ms. Tang Mui Fun and Ms. Tang Wai Man and the independent non-executive Directors are Mr. Leung Wai Ho, Mr. Siu Man Ho, Simon, Mr. Cho Wing Mou and Mr. Li Ka Fai, David.

* For identification purpose only